GNLX supply chain intelligence for Genelux Corporation: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | The Company may, from time to time, offer and sell shares of the Company's common stock, par value $0.001 per share (the 'Placement Shares'), having an aggregate offering price of up to $100,000,000,… |
| NEWSOARA-BIOPHARMA-CO-LTD | NEWSOARA-BIOPHARMA-CO-LTD | 90% | In September 2021, the Company entered into the Newsoara License Agreement with Newsoara BioPharma Co. Ltd. |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers a… |
| BMY | Bristol-Myers Squibb Company | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers… |
| BMYMP | Bristol-Myers Squibb Co | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| CADL | Candel Therapeutics, Inc. | 72% | Reciprocal relationship from CADL graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| CADL | Candel Therapeutics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| CELG-RI | CELG-RI | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| JNJ | Johnson & Johnson | 72% | d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for on… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our dru… |
| LLY | Eli Lilly and Company | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers a… |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from GNLX graph: ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers … |
| ONCY | Oncolytics Biotech Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: ials between batches from a single … |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| REPL | Replimune Group, Inc. | 72% | Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from REPL g… |
| REPL | Replimune Group, Inc. | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| TOVX | Theriva Biologics, Inc. | 72% | Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: ials between batches from a single … |
| TOVX | Theriva Biologics, Inc. | 72% | ials between batches from a single supplier or between suppliers; ● the possible breach by our third-party suppliers and service providers of our agreements with them; ● the failure of our third-part… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMY grap… |
| BMY | Bristol-Myers Squibb Company | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| BMYMP | Bristol-Myers Squibb Co | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from BMYM… |
| CADL | Candel Therapeutics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| CADL | Candel Therapeutics, Inc. | 72% | Reciprocal relationship from CADL graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. … |
| CELG-RI | CELG-RI | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| IOVA | Iovance Biotherapeutics, Inc. | 72% | Reciprocal relationship from IOVA graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| JNJ | Johnson & Johnson | 72% | d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our drugs can be commercialized, any related patent may expire or remain in force for on… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from GNLX graph: d regulatory review of any drug we may develop from our product candidates, it is possible that, before any of our dru… |
| LLY | Eli Lilly and Company | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from LLY graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate anal… |
| ONCY | Oncolytics Biotech Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| ONCY | Oncolytics Biotech Inc. | 72% | Reciprocal relationship from ONCY graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | Reciprocal relationship from REGN graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| REGN | Regeneron Pharmaceuticals, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| REPL | Replimune Group, Inc. | 72% | nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, production cleanrooms, and installed equipment, t… |
| REPL | Replimune Group, Inc. | 72% | Reciprocal relationship from REPL graph: Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The… |
| TOVX | Theriva Biologics, Inc. | 72% | Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this pr… |
| TOVX | Theriva Biologics, Inc. | 72% | g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial. Any future changes to our manufacturing … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| GNLX-DEBT-9831 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2023-12-31. |
| GNLX-DEBT-9830 | Warrants outstanding: 7500000 | 90% | xbrl warrant detail from xbrl 2024-09-30. |
| GNLX-DEBT | Debt stack $2.5M | 90% | Market cache reports total debt of $2.5M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| GNLX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 71 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| REPL | Replimune Group, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer', 'supplier'] |
| TOVX | Theriva Biologics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| LLY | Eli Lilly and Company | 100.00 | 1 | ['customer', 'supplier'] |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| CADL | Candel Therapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| ONCY | Oncolytics Biotech Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| IOVA | Iovance Biotherapeutics, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| JNJ | Johnson & Johnson | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['customer', 'supplier'] |
| AORT | Artivion, Inc. | 50.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 50.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 50.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 50.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 50.00 | 2 | |
| CVRX | CVRx, Inc. | 50.00 | 2 | |
| BLLN | BillionToOne, Inc. | 50.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 |